EO771 Xenograft Model Service for Breast Cancer

The EO771 xenograft model provides a powerful in vivo platform for studying luminal breast cancer and evaluating novel targeted therapies in a clinically relevant context. Alfa Cytology, a premier contract research organization, offers comprehensive EO771 xenograft model services, leveraging specialized expertise to accelerate your preclinical drug discovery.

Overview of EO771 Xenograft Model for Breast Cancer

The EO771 cell line is a widely utilized murine breast cancer model. Originally derived from a spontaneous mammary adenocarcinoma in a C57BL/6 mouse, it is unique for representing the Luminal A molecular subtype, meaning it expresses estrogen receptor (ER), progesterone receptor (PR), and is typically HER2 negative.

For xenograft applications, Alfa Cytology utilizes authenticated EO771 cell lines established in vivo in suitable immunocompromised mice. This model reliably recapitulates the hormone-responsive nature of clinical Luminal A breast cancer, which constitutes the majority of breast cancer cases. The EO771 model exhibits predictable growth kinetics and maintains consistent expression of ER and PR, making it an essential tool for evaluating anti-estrogen therapies, selective estrogen receptor modulators (SERMs), and novel targeted agents designed for hormone-sensitive disease.

Fig 1. EO771 cells express PARP7 and are responsive to DMXAA stimulated increases in type I interferon (IFN) signaling. (Rasmussen M., et al., 2023)

Cell Line Information: EO771

The EO771 cell line is carefully characterized by Alfa Cytology to ensure model validity.

As a leading specialist CRO, Alfa Cytology delivers high-fidelity preclinical data by strictly adhering to rigorous quality standards. Our EO771 model services encompass not only model establishment and efficacy testing but also in-depth pharmacological and histological characterization.

Our Services

Workflow of EO771 Xenograft Model Construction

The established in vivo workflow at Alfa Cytology is designed for consistency and precision. A visualized summary of the five key phases is provided below.

• Cell Prep: Validated EO771 cells are expanded in vitro, maintaining optimal health and confirmed ER+/PR+ phenotype.
• Host Selection: Immunocompromised mice suitable for accepting murine cells (e.g., Nude or severe SCID strains) are selected and screened for health.
• Inoculation: A standardized EO771 cell suspension, calibrated to a specific concentration, is combined with a Matrigel carrier and surgically injected in vivo via a specific route (e.g., mammary fat pad for orthotopic models).
• Longitudinal Monitoring: Tumor growth is tracked systematically using digital calipers, and overall animal health is monitored to establish robust growth curves.
• Randomization: To minimize bias, mice are randomized into specific treatment and control groups based on initial tumor volume.

Fig 2. EO771 Xenograft Model Construction Workflow

Case Study - EO771 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the EO771 xenograft model was utilized to evaluate the synergistic efficacy of a novel selective estrogen receptor degrader (SERD) candidate when combined with standard chemotherapy. Our specialized team achieved highly reproducible tumor take and uniform growth kinetics across all cohorts. The study successfully demonstrated that the combination therapy induced substantial tumor regression compared to either agent alone.

Why Choose Alfa Cytology?

• Luminal Model Expertise: Dedicated proficiency in modeling hormone-responsive in vivo endpoints.
• Highly Characterized Models: Routine validation of ER/PR expression and response to standard controls (e.g., Tamoxifen).
• Flexible Platforms: Capable of both xenograft and syngeneic studies with EO771 to suit specific immunity requirements.
• Integrated Solutions: Full pharmacological support, including PK analysis and IHC for hormone markers.

Contact Us

Ready to accelerate your drug discovery program for luminal breast cancer? Alfa Cytology provides the expert in vivo platforms and technical depth necessary to validate your novel therapeutics. Please reach out to us today to speak with a senior scientist about your research goals or to discuss a customized EO771 study design.

For research use only. Not intended for any clinical use.